Baxter International Inc. (BAX) Stock AnalysisBAXBaxter International Inc.

Baxter International Inc. is a global medtech company. Its segments include Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. The Medical Products and Therapies segment includes sales of sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems and Technologies segment includes sales of its connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia, and drug compounding. Its products are used in hospitals, rehabilitation centers, ambulatory surgery centers, and others. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Baxter International Inc appears to be a good buy right now, especially considering its current price of $24.35, which is below several analyst price targets, including $28 from BofA and $29 from TD Cowen. The company has shown a year-to-date change of +24.87%, reflecting strong momentum. Additionally, the RSI is at 63.485, indicating bullish momentum, while the forward P/E ratio of 11.57 suggests that the stock is reasonably valued compared to its earnings potential. However, a key risk is the recent net income fluctuations, with a loss of $1.12 billion reported in Q4 2025, which could impact future profitability.